FDA: Data suggests Abbott’s rapid coronavirus diagnostic test is delivering inaccurate results

- Advertisement -
KEY POINTS
  • The U.S. Food and Drug Administration issued an alert on Thursday saying there is early data that suggests  Abbott Labs’ rapid coronavirus diagnostic test for Covid-19 may be delivering inaccurate results.
  • Specifically, the Abbott ID NOW test may return false negative results, the FDA said.
- Advertisement -
- Advertisement -
- Advertisement -
A box containing a 5-minute test for COVID-19 from Abbott Laboratories is pictured during the daily briefing on the novel coronavirus, COVID-19, in the Rose Garden of the White House in Washington, DC, on March 30, 2020.
A box containing a 5-minute test for COVID-19 from Abbott Laboratories is pictured during the daily briefing on the novel coronavirus, COVID-19, in the Rose Garden of the White House in Washington, DC, on March 30, 2020.
Mandel Ngan | AFP | Getty Images

The U.S. Food and Drug Administration issued an alert on Thursday saying there is early data that suggests  Abbott Labs’ rapid Covid-19 diagnostic test for may be delivering inaccurate results.

Specifically, the Abbott ID NOW test may return false negative results, the FDA said.

“We are still evaluating the information about inaccurate results and are in direct communications with Abbott about this important issue,” said Tim Stenzel, director of the Office of In Vitro Diagnostics and Radiological Health at the FDA’s Center for Devices and Radiological Health, in a statement. “We will continue to study the data available and are working with the company to create additional mechanisms for studying the test.”

Despite these concerns, ID NOW may continue to be used to correctly identify positive cases, but negative results may need confirmation from a high-sensitivity authorized molecular test Stenzel said.

Abbott’s share price dropped following the FDA alert, and it is down more than 3% in after-hours trading.

The FDA alert comes a day after researchers at New York University published a study claiming the ID NOW test missed a third of samples collected with nasopharyngeal swabs that tested positive with a test from rival Cepheid.

Abbott Labs refuted the NYU study’s claims that its rapid coronavirus diagnostic test could be missing nearly half of positive cases.

“While we understand no test is perfect, test outcomes depend on a number of factors including patient selection, specimen type, collection, handling, storage, transport and conformity to the way the test was designed to be run,” Abbott said in a statement on Thursday. “ID NOW is intended to be used near the patient with a direct swab test method.”

Home of Science
Follow me

- Advertisement -

Discover

Sponsor

Latest

What Is Mesothelioma?

Mesothelioma is a rare form of cancer that occurs mainly in the mesothelium, the protective layer that surrounds the organs and the interior of...

Former Hollywood movie CEO charged with $30M fraud

A former Hollywood movie executive is charged with embezzling millions of dollars in investor funds, the FBI alleged in a complaint that was unsealed Friday. William Sadleir, 66, is...

The Q2 2019 Global Venture Capital Report: A Market Gone Sideways

  For the global venture capital market, Q2 2019 breaks one trend and makes another. Using data and projections from Crunchbase, this report from Crunchbase News dives deep...

China snaps up Russia’s expensive Urals oil in thirst for sour barrels

China's refiners have purchased a quarter of Russia's Urals oil exports planned for June in the Baltic despite record high premiums for the grade...

Method for thawing surfaces in seconds is developed by scientists

A much more efficient method, at least according to the press release, to remove ice from the surface, was developed by a group of...
Home of Science
Follow me